Across TCGA pan-cancer cohorts, MYBPC1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYBPC1 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MYBPC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYBPC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and UCS show a favorable association.

OV, UCEC, and LUAD are the cancer types where MYBPC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.023	0.844	<.001	36	view →
UCEC	DFS	Median	All	0.948	0.599	.001	36	view →
LUAD	OS	Median	II,III,IV	0.198	0.711	<.001	24	view →
LIHC	OS	Median	All	0.008	0.775	<.001	6	view →
UCS	DFS	Median	All	1.000	0.224	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MYBPC1 tumor-vs-normal RNA expression · all MYBPC1 data types